Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study

Tosukhowong, Piyaratana; Boonla, Chanchai; Dissayabutra, Thasinas; Kaewwilai, Lalita; Muensri, Sasipa; Chotipanich, Chanisa; Joutsa, Juho; Rinne, Juha O.; Bhidayasiri, Roongroj

doi:10.1016/j.jns.2016.05.056

Cited by 43 publications

(32 citation statements)

References 49 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A double-blind, placebo-controlled, Phase IV trial was designed in Thailand to compare HMS 90 R (an immune system stimulant) vs. soy protein (as placebo), by the dose of 1 sachet (10 g) 2 times/day as adjuvant therapy in 38 individuals with idiopathic PD. No significant clinical outcomes were observed in biomarkers of oxidative stress (glutathione), plasma amino acids, and the brain function in both groups (Tosukhowong et al, 2016).…”

Section: Soy Isoflavonesmentioning

confidence: 84%

Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

Polyphenols can act as proteasome-inhibitors or may modulate the proteasome activity, thereby improving neurodegenerative disorders by means of accumulation of ubiquitinated proteins, suppression of neuronal apoptosis, reduction of neurotoxicity, and improvement of synaptic plasticity and transmission. HIGHLIGHTS • Aberrant accumulation of intracellular ubiquitin-positive inclusions associated to neurodegenerative disorders. • Polyphenols, can act as proteasome-inhibitors or may modulate the proteasome activity. • Polyphenols can manage neurodegenerative impairments by targeting the ubiquitin-proteasome system (UPS). • Polyphenols exert UPS inhibitory activity, resulting in the accumulation of ubiquitinated proteins, suppression of neuronal apoptosis, reduction of neurotoxicity, and improvement of synaptic plasticity and transmission.

show abstract

Section: Soy Isoflavonesmentioning

confidence: 84%

Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As such, BCAA supplementation is used by athletes [ 98 ] and prescribed for weight regulation [ 99 ] and management of sarcopenia [ 9 ]. Dysregulated serum levels of BCAAs have also been observed in neurodegenerative diseases such as Huntington's [ 100 ], Parkinson's [ 101 ] and Alzheimer's [ 102 ]. Thus, regulated BCAA supplementation or consumption may have wide-reaching benefits in several neurodegenerative and neuromuscular disorders.…”

Section: Discussionmentioning

confidence: 99%

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice

et al. 2018

View full text Add to dashboard Cite

The circadian glucocorticoid-Krüppel-like factor 15-branched-chain amino acid (GC-KLF15-BCAA) signaling pathway is a key regulatory axis in muscle, whose imbalance has wide-reaching effects on metabolic homeostasis. Spinal muscular atrophy (SMA) is a neuromuscular disorder also characterized by intrinsic muscle pathologies, metabolic abnormalities and disrupted sleep patterns, which can influence or be influenced by circadian regulatory networks that control behavioral and metabolic rhythms. We therefore set out to investigate the contribution of the GC-KLF15-BCAA pathway in SMA pathophysiology of Taiwanese Smn−/−;SMN2 and Smn2B/− mouse models. We thus uncover substantial dysregulation of GC-KLF15-BCAA diurnal rhythmicity in serum, skeletal muscle and metabolic tissues of SMA mice. Importantly, modulating the components of the GC-KLF15-BCAA pathway via pharmacological (prednisolone), genetic (muscle-specific Klf15 overexpression) and dietary (BCAA supplementation) interventions significantly improves disease phenotypes in SMA mice. Our study highlights the GC-KLF15-BCAA pathway as a contributor to SMA pathogenesis and provides several treatment avenues to alleviate peripheral manifestations of the disease. The therapeutic potential of targeting metabolic perturbations by diet and commercially available drugs could have a broader implementation across other neuromuscular and metabolic disorders characterized by altered GC-KLF15-BCAA signaling.

show abstract

“…Thus, dietary supplementation with cysteine or cysteine-rich foods has proved beneficial in several neurodegenerative diseases involving oxidative stress. For example, intake of whey protein, which has high levels of cysteine, has been linked to decreased oxidative stress, increased glutathione content, and improved antioxidant status in patients with Parkinson's disease (35). Supplementation with NAC, a more stable cysteine derivative, has also proved beneficial in elderly subjects, eliciting improved motor function (36,37).…”

Section: Discussionmentioning

confidence: 99%

Golgi stress response reprograms cysteine metabolism to confer cytoprotection in Huntington’s disease

Sbodio

Snyder

Paul

2018

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Golgi stress response is emerging as a physiologic process of comparable importance to endoplasmic reticulum (ER) and mitochondrial stress responses. However, unlike ER stress, the identity of the signal transduction pathway involved in the Golgi stress response has been elusive. We show that the Golgi stressor monensin acts via the PKR-like ER kinase/Activating Transcription Factor 4 pathway. ATF4 is the master regulator of amino acid metabolism, which is induced during amino acid depletion and other forms of stress. One of the genes regulated by ATF4 is the biosynthetic enzyme for cysteine, cystathionine γ-lyase (CSE), which also plays central roles in maintenance of redox homeostasis. Huntington's disease (HD), a neurodegenerative disorder, is associated with disrupted cysteine metabolism caused by depletion of CSE leading to abnormal redox balance and stress response. Thus, restoring CSE function and cysteine disposition may be beneficial in HD. Accordingly, we harnessed the monensin-ATF4-signaling cascade to stimulate CSE expression by preconditioning cells with monensin, which restores cysteine metabolism and an optimal stress response in HD. These findings have implications for treatment of HD and other diseases associated with redox imbalance and dysregulated ATF4 signaling.

show abstract

Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study

Cited by 43 publications

References 49 publications

Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases

Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice

Golgi stress response reprograms cysteine metabolism to confer cytoprotection in Huntington’s disease

Contact Info

Product

Resources

About